Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (266)	6/25/1999 1:51:00 PM
From: Mike McFarland	Respond to of 805

Absolutely Rick, and your contributions are always welcome--even when you're right and it makes me look like a naive newbie. Hey, at least I am consistent {:-(} Here is the article by the way from the Providence Journal... Test failure could prove hazardous to biotech firm's health projo.com --but let's look forward CytoTherapeutics does not have a corporate partner to fund the stem cells program, however. Razee said the firm's researchers have promising early stage data and management is negotiating with ''interested'' potential partner. CTI has about a year of cash left...they'll need that partner. I am not adding any shares at these levels, I took a chance and loaded up to a "full position" before the Astra trials were announced. There is always the temptation to average down, but my shares cost just over a buck, and that is an okay entry point for the stem cell angle. I just keep telling myself that other folks have been in this at much higher prices... And besides, this is exactly what one has to expect from biotech investing. You just hope that a couple of one's picks turn out to be the big winners, paying for the stinkers, and makes it all worthwhile.